Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

VC accommodates Visiogen

This article was originally published in The Gray Sheet

Executive Summary

Synchrony dual optic accommodating intraocular lens maker raises $24 million in a financing round to support clinical development and other efforts relating to its first product. The lead investor was CMEA Ventures. Other supporters included Foundation Medical Partners and Three Arch Partners, according to a Feb. 28 announcement. Synchrony obtained a CE mark in June 2006 and is in pivotal trials in the United States. The IOL, which incorporates a customized spring-loading component to change the eye's focus from near to far, has been implanted in more than 400 patients worldwide, Visiogen says. Accommodating IOLs like Synchrony, HumanOptics' 1CU and Eyeonics' CrystaLens are designed to more closely mimic the behavior of natural lenses to better capture distance, intermediate and near vision in a single product (1"The Gray Sheet" Oct. 9, 2006, p. 12)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024556

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel